PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VERU vs. VIR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VERU and VIR is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

VERU vs. VIR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Veru Inc. (VERU) and Vir Biotechnology, Inc. (VIR). The values are adjusted to include any dividend payments, if applicable.

-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2025FebruaryMarchApril
-73.78%
-60.56%
VERU
VIR

Key characteristics

Sharpe Ratio

VERU:

-0.49

VIR:

-0.44

Sortino Ratio

VERU:

-0.20

VIR:

-0.33

Omega Ratio

VERU:

0.97

VIR:

0.96

Calmar Ratio

VERU:

-0.57

VIR:

-0.42

Martin Ratio

VERU:

-1.02

VIR:

-1.22

Ulcer Index

VERU:

55.40%

VIR:

32.17%

Daily Std Dev

VERU:

114.45%

VIR:

89.26%

Max Drawdown

VERU:

-98.44%

VIR:

-93.75%

Current Drawdown

VERU:

-97.72%

VIR:

-93.34%

Fundamentals

Market Cap

VERU:

$79.44M

VIR:

$758.40M

EPS

VERU:

-$0.21

VIR:

-$3.83

Total Revenue (TTM)

VERU:

$10.61M

VIR:

$16.73M

Gross Profit (TTM)

VERU:

$4.03M

VIR:

$11.69M

EBITDA (TTM)

VERU:

-$29.34M

VIR:

-$462.00M

Returns By Period

In the year-to-date period, VERU achieves a -16.57% return, which is significantly higher than VIR's -24.66% return.


VERU

YTD

-16.57%

1M

12.04%

6M

-37.34%

1Y

-64.30%

5Y*

-29.86%

10Y*

-16.63%

VIR

YTD

-24.66%

1M

-22.66%

6M

-27.14%

1Y

-38.35%

5Y*

-28.53%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VERU vs. VIR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VERU
The Risk-Adjusted Performance Rank of VERU is 3232
Overall Rank
The Sharpe Ratio Rank of VERU is 3030
Sharpe Ratio Rank
The Sortino Ratio Rank of VERU is 3737
Sortino Ratio Rank
The Omega Ratio Rank of VERU is 3737
Omega Ratio Rank
The Calmar Ratio Rank of VERU is 2020
Calmar Ratio Rank
The Martin Ratio Rank of VERU is 3535
Martin Ratio Rank

VIR
The Risk-Adjusted Performance Rank of VIR is 3232
Overall Rank
The Sharpe Ratio Rank of VIR is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of VIR is 3434
Sortino Ratio Rank
The Omega Ratio Rank of VIR is 3535
Omega Ratio Rank
The Calmar Ratio Rank of VIR is 3131
Calmar Ratio Rank
The Martin Ratio Rank of VIR is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VERU vs. VIR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Veru Inc. (VERU) and Vir Biotechnology, Inc. (VIR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VERU, currently valued at -0.49, compared to the broader market-2.00-1.000.001.002.00
VERU: -0.49
VIR: -0.44
The chart of Sortino ratio for VERU, currently valued at -0.20, compared to the broader market-6.00-4.00-2.000.002.004.00
VERU: -0.20
VIR: -0.33
The chart of Omega ratio for VERU, currently valued at 0.97, compared to the broader market0.501.001.502.00
VERU: 0.97
VIR: 0.96
The chart of Calmar ratio for VERU, currently valued at -0.57, compared to the broader market0.001.002.003.004.00
VERU: -0.57
VIR: -0.42
The chart of Martin ratio for VERU, currently valued at -1.01, compared to the broader market-5.000.005.0010.0015.0020.00
VERU: -1.02
VIR: -1.22

The current VERU Sharpe Ratio is -0.49, which is comparable to the VIR Sharpe Ratio of -0.44. The chart below compares the historical Sharpe Ratios of VERU and VIR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
-0.49
-0.44
VERU
VIR

Dividends

VERU vs. VIR - Dividend Comparison

Neither VERU nor VIR has paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
VERU
Veru Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.57%
VIR
Vir Biotechnology, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

VERU vs. VIR - Drawdown Comparison

The maximum VERU drawdown since its inception was -98.44%, which is greater than VIR's maximum drawdown of -93.75%. Use the drawdown chart below to compare losses from any high point for VERU and VIR. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%NovemberDecember2025FebruaryMarchApril
-97.72%
-93.34%
VERU
VIR

Volatility

VERU vs. VIR - Volatility Comparison

Veru Inc. (VERU) has a higher volatility of 35.39% compared to Vir Biotechnology, Inc. (VIR) at 21.28%. This indicates that VERU's price experiences larger fluctuations and is considered to be riskier than VIR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%NovemberDecember2025FebruaryMarchApril
35.39%
21.28%
VERU
VIR

Financials

VERU vs. VIR - Financials Comparison

This section allows you to compare key financial metrics between Veru Inc. and Vir Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab